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Purpose: Hemorrhage and thrombosis predisposing to myocardial infarction, multiple
organ failure, and thromboembolism account for the majority of the morbidity and
mortality associated with repair of ruptured and nonruptured abdominal aortic
aneurysms (AAAs). The aim of this study was to examine coagulation and fibrinolysis in
patients operated on for ruptured and nonruptured infrarenal AAAs.
Methods: Ten patients operated on for ruptured and 9 patients operated on for nonrup-
tured AAAs were studied. Tissue plasminogen activator (t-PA) antigen, thrombin-
antithrombin (TAT), and D-dimer were measured before induction of anesthesia.
Plasminogen activator inhibitor (PAI) activity, t-PA activity, and prothrombin fragment
(PF) 1+2 were measured before induction of anesthesia, immediately before aortic clamp
release, and 5 minutes and 24 hours after aortic clamp release.
Results: Preoperatively, ruptured AAA was associated with significantly elevated t-PA
antigen (median 15.7 ng/mL, range 9.0 to 22.1 ng/mL versus nonrupture: median
6.6 ng/mL, range 4.7 to 16.4 ng/mL; P < .01, Mann-Whitney test), increased PAI
activity (median 36.5 arbitrary units/mL, range 20.6 to 38.8 arbitrary units/mL ver-
sus nonrupture: median 8.2 arbitrary units/mL, range 3.2 to 21.7 arbitrary
units/mL; P < .001), reduced t-PA activity (median 0.12 IU/mL, range 0.06 to 0.4
IU/mL versus nonrupture: median 0.49 IU/mL, range 0.14 to 3.2 IU/mL; P < .01),
elevated TAT (median 135.5 µg/L, range 61.2 to 209.4 µg/L versus nonrupture:
median 21.6 µg/L, range 6.6 to 180.4 µg/L; P < .02) and elevated PF 1+2 (median
9.0 nmol/L, range 5.4 to 11.6 nmol/L versus nonrupture: median 2.2 nmol/L, range
0.7 to 7.1 nmol/L, P < .001). There was no significant difference in preoperative D-
dimer levels (median 3460 ng/mL, range 1236 to 7860 ng/mL versus nonrupture:
median 1642 ng/mL, range 728 to 5334 ng/mL; P = .07). The differences in PAI
activity, t-PA activity, and PF 1+2 persisted throughout the course of surgery, but
there was no significant difference between the groups at 24 hours.
Conclusion: These novel data demonstrate that ruptured AAA repair is associated with
inhibition of systemic fibrinolysis and intense thrombin generation. Similar changes
are seen in nonruptured AAA but are of a lesser magnitude. This procoagulant state
may contribute to the microvascular and macrovascular thrombosis that leads to
myocardial infarction, multiple organ failure, and thromboembolism. (J Vasc Surg
1999;30:641-50.)
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Repair of ruptured and nonruptured abdominal
aortic aneurysms (AAAs) is associated with an opera-
tive mortality rate of approximately 35% to 50%1,2
and 5% to 15%,3 respectively. The great majority of
these deaths are due to myocardial infarction, multi-
ple organ failure, and thromboembolism, all of which
may be related to microvascular and macrovascular
thrombosis developing as a result of a procoagulant
state.2,4,5 Perhaps surprisingly, therefore, previous
authors have suggested that supraceliac aortic cross-
clamping and thoracoabdominal aortic aneurysm
repair are associated with increased fibrinolysis,
which may be due to reduced hepatic blood flow.6,7
Furthermore, animal studies suggest that infrarenal
aortic clamping and isolated lower body ischemia are
also associated with elevated levels of fibrinolytic
markers.8 With respect to elective infrarenal aortic
reconstruction, studies are few and contradictory.9-12
Although these data have been used to support the
use of antifibrinolytic agents in patients undergoing
operation for ruptured AAA,13 careful review of the
literature reveals that the precise nature of the serial
changes in hemostatic derangement in such patients
has not previously been studied. The aims of this
study were to examine serial markers of thrombin
generation and fibrinolysis during the course of
emergent surgery for ruptured infrarenal AAA and to
compare these with those undergoing elective repair
of nonruptured infrarenal AAA.
METHODS
Patients. Ten patients (8 men and 2 women of
median age 76 years, range 71 to 86 years) operated
on for ruptured and 9 patients (8 men and 1 woman
of median age 69 years, range 58 to 80 years) oper-
ated on for asymptomatic nonruptured infrarenal
AAA were prospectively studied. Lothian Region
Ethical Committee approval was obtained as was
fully informed written consent from all patients.
In patients operated on for ruptured AAA, the
median (range) delay between the onset of symp-
toms of rupture and hospital admission was 5 (3 to
14) hours. All patients had at least one documented
episode of hypotension (systolic blood pressure less
than 100 mm Hg) before surgery. In patients under-
going operation for nonruptured AAA, the median
(range) anteroposterior diameter of the aneurysm
measured by abdominal ultrasound scan was 6.5
(5.5 to 8.0) cm. No patient in either group had a
history of liver disease or was taking oral anticoagu-
lant medication before admission. Liver function
tests were only available preoperatively in elective
cases and were all normal. Three patients with rup-
tured AAA and four with nonruptured AAA were
taking regular aspirin before admission.
Operative methods. Ruptured AAA was defined
by the presence of fresh retroperitoneal blood at oper-
ation. No patient had intraperitoneal rupture. Patients
with rupture had general anesthesia, and patients with
nonruptured AAA had combined general and epidur-
al anesthesia. All patients underwent AAA repair
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Fig 1. Overview of extrinsic coagulation and fibrinolytic
systems. Markers studied are shown in boxes. Extrinsic
coagulation system: tissue injury, endothelial activation
and injury, and monocyte activation lead to tissue factor
expression, which triggers the extrinsic coagulation cas-
cade. This leads to conversion of prothrombin to throm-
bin with release of PF 1+2. Excess thrombin is inactivated
by antithrombin III (main thrombin inhibitor) with for-
mation of TAT. Fibrinolytic system: endothelial activation
and injury lead to release of t-PA, which converts plas-
minogen to the active enzyme plasmin, which, in turn,
leads to breakdown of fibrinogen, fibrin and fibrin clot to
fibrin degradation products such as D-dimer. PAI is the
naturally occurring inhibitor of t-PA and is released from
endothelium, hepatocytes and platelets.
through a transverse supraumbilical incision with
infrarenal aortic clamping, which is the standard
approach in this institution. No patients required
supraceliac aortic clamping. No patients with rup-
tured AAA were systemically heparinized. Patients
with nonruptured AAA were given an intravenous
bolus of 5000 units heparin immediately before aor-
tic clamp placement. No patient received protamine
sulfate or mannitol infusion because this is the stan-
dard policy in this institution. A Dacron tube graft
was inserted in 13 patients (nine with rupture, four
with nonrupture), aortobi-iliac graft in five (one with
rupture, four with nonrupture), and aortobifemoral
graft in one patient with nonruptured AAA.
Markers of thrombin generation and fibrino-
lysis. The extrinsic coagulation and fibrinolytic sys-
tems are summarized in Fig 1. Plasma levels of pro-
thrombin fragment (PF) 1+2 (normal range, 0.4 to
1.1 nmol/L) and thrombin-antithrombin complex
(TAT) (normal range, 1.0 to 4.1 µg/L) were assayed
as markers of thrombin generation, and tissue plas-
minogen activator (t-PA) activity (normal range, 0.2
to 2.0 IU/mL), t-PA antigen (normal range, 1 to 12
ng/mL), plasminogen activator inhibitor (PAI)
activity (normal range, less than 15 arbitrary units
[AU]/mL), and fibrin degradation product D-
dimer (normal range, 630 to 850 ng/mL) as mark-
ers of fibrinolysis. Hematocrit (normal range, 0.37
to 0.54), platelet count (normal range, 150 to 350
× 109/L), fibrinogen (normal range, 1.5 to 4.0
g/L), prothrombin time (PT) (normal range, 10.5
to 14.5 seconds) and activated partial thromboplas-
tin time (aPTT) (normal range, 28 to 40 seconds),
and C-reactive protein (CRP) (normal range, less
than 10 mg/L) were also measured (Table I).
Sample collection. The sampling points were
chosen to reflect the maximum effect of each of the
three pathophysiologic phases of ruptured AAA
repair (Fig 2). Blood was sampled from an indwelling
radial arterial line immediately before the induction
of anesthesia (sample A), immediately before release
of the aortic clamp (sample B), and 5 minutes (sam-
ple C) and 24 hours (sample D) after aortic clamp
release. t-PA antigen, D-dimer and TAT were mea-
sured at sample point A. Hematocrit, platelet count,
fibrinogen, PT, aPTT, CRP, t-PA activity, PAI activi-
ty, and PF 1+2 were measured at all four sample
points. Samples were placed immediately on ice and
centrifuged within 30 minutes of collection at 3000
revolutions per minute for 30 minutes at 4˚C (equiv-
alent to 1400g). Plasma and serum were separated
and stored at –70˚C for later batch analysis.
Statistical methods. The Mann-Whitney test
was used to compare groups of patients. Because the
data were not normally distributed, the Spearman
rank test was used to correlate the degree of preop-
erative hypotension and the operative blood loss with
the levels of hemostatic markers in patients operated
on for ruptured AAA. A probability value of less than
.05 was regarded as statistically significant.
RESULTS
Clinical data. Clinical and operative data for
both groups of patients are summarized in Table II.
During operation, no patients with nonruptured
AAA received inotropic support. Three patients with
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 4 Adam et al 643
Table I. Assays of coagulation and fibrinolysis
Assay Tube Volume (mL) Assay Manufacturer Normal range
Hematocrit 0.37-0.54
Platelet count EDTA (1.6 mg/mL) 2.7 SYSMEX NE 8000 150-350 × 109/L
CRP Clot activator 9.0 ELISA DAKO, Denmark < 10 mg/L
Fibrinogen 1.5-4.0 g/L
PT ACL 300 10.5-14.5 s
aPTT 28-40 s
TAT Enzygnost TAT micro; Behring 1.0-4.1 µg/L
Diagnostics
PF 1+2 Sodium citrate (0.106 mol/L) 3.0 ELISA Enzygnost PF 1+2 micro; Behring 0.4-1.1 nmol/L
Diagnostics
D-dimer Asserachrom D-Di; Diagnostica 630-850 ng/mL
Stago, France
t-PA antigen Coaliza t-PA; Chromogenix, Sweden 1-12 ng/mL
PAI activity Chromogenic assay Coaset PAI; Chromogenix, Sweden
(amidolytic method) < 15 AU/mL
t-PA activity Strong acid citrate (Stabilyte; Coatest t-PA; 0.2-2.0 IU/mL
Biopool, Sweden) 4.5 Chromogenix, Sweden
EDTA, Ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; AU, arbitrary units.
rupture received adrenaline infusion and five
received dopamine infusion. All patients with rup-
ture were admitted to the intensive therapy unit
postoperatively for ventilatory support. The median
(range) duration of intensive therapy unit stay was
72 (13 to 244) hours. The median (range) duration
of ventilatory support was 19 (9 to 142) hours. All
patients operated on for nonruptured AAA were
admitted to the surgical high dependency unit post-
operatively, and no patient was admitted to the
intensive therapy unit or required ventilatory sup-
port. Seven patients operated on for rupture and
four operated on for nonruptured AAA developed
major postoperative complications (Table III). All
patients survived to 24 hours after repair. Two
patients with rupture died in hospital of acute respi-
ratory distress syndrome and acute renal failure on
postoperative day 10 and of pneumonia and critical
lower limb ischemia on postoperative day 21. There
were no deaths after repair of nonruptured AAA.
Hematocrit, platelet count, fibrinogen, PT,
aPTT, and CRP. The median (range) values for
hematocrit, the standard tests of hemostasis (platelet
count, PT, aPTT, and fibrinogen) and CRP are
shown in Table IV.
In patients operated on for ruptured AAA, there
was no significant relationship between the degree
of preoperative hypotension and any of the standard
tests of hemostasis. There was, however, a significant
negative correlation between operative blood loss
and fibrinogen level immediately before (r = –0.694,
P = .026) and 5 minutes after aortic clamp release (r
= –0.75, P = .012), and also platelet count 5 minutes
after aortic clamp release (r = –0.726, P = .018); and
a significant positive correlation between operative
blood loss and PT immediately before aortic clamp
release (r = +0.823, P = .003), and aPTT immedi-
ately before (r = +0.787, P = .007) and 5 minutes
after aortic clamp release (r = +0.64, P = .046).
Markers of thrombin generation. Before oper-
ation, TAT levels were elevated above the normal
range in all patients. Levels were significantly higher
in patients with ruptured AAA (median 135.5 µg/L,
range 61.2 to 209.4 µg/L) than in those with non-
ruptured AAA (median 21.6 µg/L, range 6.6 to
180.4 µg/L; P < .02, Mann-Whitney test) (Fig 3).
Before and during operation, PF 1+2 levels were also
significantly higher in patients undergoing repair of
ruptured AAA when compared with those undergo-
ing repair of nonruptured AAA. At 24 hours there
was no significant difference in PF 1+2 levels
between the groups (Table V and Fig 4). There was
no significant relationship between the degree of pre-
operative hypotension or operative blood loss and
any of the markers of thrombin generation.
Markers of fibrinolysis. Before operation, 
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Fig 2. Schematic view of pathophysiology of ruptured
AAA repair. Pathophysiology of ruptured AAA repair can
be divided into three phases. First, there is a period of
whole body hypoperfusion due to hypovolemic shock.
Second, there is a period of profound lower body ischemia
after aortic clamp placement. Finally, if repair is successful,
there is a period of reperfusion.
Fig 3. Individual data points for levels of TAT, t-PA anti-
gen, and fibrin degradation product D-dimer immediately
before induction of anesthesia (sample A) in 10 patients
with ruptured AAA (black squares) and 9 patients with
nonruptured AAA (black circles). Normal ranges for TAT
(1.0 to 4.1 µg/L), t-PA antigen (1 to 12 ng/mL), and D-
dimer (630 to 850 ng/mL) are shown by horizontal lines.
NS, Not significant.
t-PA antigen levels were significantly higher in
patients with ruptured AAA (median 15.7 ng/mL,
range 9.0 to 22.1 ng/mL) compared with those
with nonruptured AAA (median 6.6 ng/mL, range
4.7 to 16.4 ng/mL; P < .005, Mann-Whitney test).
Before operation, there was no significant difference
in the D-dimer levels between the ruptured AAA
(median 3460 ng/mL, range 1236 to 7860
ng/mL) and nonruptured AAA group (median
1642 ng/mL, range 728 to 5334 ng/mL; P = .07,
Mann-Whitney test) (Fig 3). Before and during
operation, t-PA activity was significantly lower in
patients undergoing repair of ruptured AAA when
compared with those undergoing repair of nonrup-
tured AAA (Table V and Fig 5). At 24 hours there
was no significant difference in t-PA activity between
the groups. Before and during operation, PAI activ-
ity was significantly higher in patients undergoing
repair of ruptured AAA when compared with those
undergoing repair of nonruptured AAA. At 24
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Table II. Clinical and operative data in 10 patients operated on for ruptured and 9 patients operated on
for nonruptured infrarenal AAAs
Ruptured AAA, Nonruptured AAA,
median (range) (n = 10) median (range) (n = 9) P value*
Preoperative
Crystalloid administration (L) 0.5 (0.1-4.0) —
Colloid administration (L) 0 (0-1.5) —
Intraoperative
Operation time (min) 105 (70-205) 160 (85-285) NS
Aortic clamp time (min) 60 (30-125) 70 (25-150) NS
Measured blood loss (L) 2.3 (1.0-6.4) 2.8 (1.0-6.0) NS
Crystalloid administration (L) 2.0 (0.5-3.5) 2.0 (1.0-4.0) NS
Colloid administration (L) 1.5 (0-2.3) 2.0 (0.5-3.8) NS
RCC administration (units) 8 (6-11) 4 (0-10) 0.02
FFP administration (units) 2 (0-6) 0 (0-2) NS
Platelet administration (bags)† 1 (0-1) 0 (0-1) NS
NS, Not significant; RCC, red cell concentrate (300 mL); FFP, fresh frozen plasma (300 mL).
*Mann-Whitney test.
†One bag of platelet transfusion = 4 pooled units (250 mL).
Fig 4. Individual data points for PF 1+2 immediately
before induction of anesthesia (sample A), immediately
before release of aortic clamp (sample B), and 5 minutes
(sample C) and 24 hours (sample D) after aortic clamp
release in 10 patients operated on for ruptured (black
squares) and 9 patients operated on for nonruptured
(black circles) infrarenal AAA. Normal range for PF 1+2 is
0.4 to 1.1 nmol/L and is shown by the horizontal line.
NS, Not significant.
Fig 5. Individual data points for t-PA activity immediate-
ly before induction of anesthesia (sample A), immediately
before release of aortic clamp (sample B), and 5 minutes
(sample C) and 24 hours (sample D) after aortic clamp
release in 10 patients operated on for ruptured (black
squares) and 9 patients operated on for nonruptured
(black circles) infrarenal AAA. Normal range for t-PA activ-
ity is 0.2 to 2.0 IU/mL and is shown by the horizontal
line. NS, Not significant.
hours there was no significant difference in PAI
activity between the groups (Table V and Fig 6).
There was no significant relationship between the
degree of preoperative hypotension or operative
blood loss and any of the markers of fibrinolysis.
Coagulation and fibrinolytic data for two patients
who died after ruptured AAA repair compared with
eight who survived are shown in Table VI.
DISCUSSION
The principal finding of the present study is that
emergency repair of ruptured AAA is associated with
intense thrombin generation (as demonstrated by
elevated TAT and PF 1+2 levels) and inhibition of
systemic fibrinolysis (as demonstrated by elevated t-
PA antigen, reduced t-PA activity, and elevated PAI
activity). This procoagulant state is present before
surgery, persists throughout the period of operation,
and has largely resolved 24 hours after operation.
Furthermore, similar changes are observed in a pro-
portion of patients undergoing elective repair of
nonruptured AAA but are of much less magnitude.
At first sight, these novel findings appear to con-
tradict a previous study that reported supraceliac
aortic cross-clamping to be associated with increased
fibrinolysis.6 One reason for this apparent discrepan-
cy may be due to the measurement of t-PA antigen
as opposed to the measurement of t-PA activity. This
failure to measure activity, as well as antigen, in the
present study might have led to the erroneous con-
clusion that ruptured AAA was, indeed, associated
with enhanced fibrinolysis. However, it is increas-
ingly apparent that t-PA antigen levels primarily
reflect the level of inactive circulating t-PA/PAI
complexes. This contention is demonstrated by the
present study, where elevated t-PA antigen is, in fact,
associated with markedly elevated PAI activity and
markedly depressed t-PA activity, consistent with a
procoagulant state.14,15
Given that repair of ruptured aortic aneurysm
and a proportion of elective aneurysm operations are
associated with a procoagulant state,9,10 two impor-
tant questions need to be addressed.
First, are the presence and the intensity of the
procoagulant state associated with poor outcome as
a result of microvascular and macrovascular throm-
botic events? Although the changes in coagulation
and fibrinolysis observed in the present study have
been associated with myocardial injury,14,16-19 mul-
tiple organ failure,20,21 and stroke22 in other patient
groups, it is not possible to answer this question
directly from the present data for two reasons. Only
data for patients who survived for 24 hours are
included in the present analysis. Data for those who
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Fig 6. Individual data points for PAI activity immediately
before induction of anesthesia (sample A), immediately
before release of aortic clamp (sample B), and 5 minutes
(sample C) and 24 hours (sample D) after aortic clamp
release in 10 patients operated on for ruptured (black
squares) and 9 patients operated on for nonruptured (black
circles) infrarenal AAA. Normal range for PAI activity is less
than 15 AU/mL and is shown by the horizontal line.
NS, Not significant.
Table III. Postoperative complications and proce-
dures in 7 patients operated on for ruptured and 4
patients operated on for nonruptured infrarenal AAAs
Ruptured AAA Nonruptured
(n = 7) AAA (n = 4)
Cardiovascular
Atrial fibrillation 3 1
Congestive cardiac failure 4 2
Myocardial infarction 1 0
Stroke 1 0
Lower limb critical ischemia 2 1
Deep venous thrombosis 0 1
Respiratory
Chest infection 6 2
Respiratory failure 3 0
Acute respiratory distress 1 0
syndrome
Acute renal failure 2 1
Disseminated intravascular 1 0
coagulopathy
Sepsis syndrome 1 0
Colon ischemia 1 0
Total parenteral nutrition 3 0
Inotropic support
Adrenaline 3 0
Renal dose dopamine 6 0
Reoperation 1* 1†
*Laparotomy for intra-abdominal hemorrhage, femoral thrombec-
tomy, Hartmann’s procedure for colon ischemia, drainage of
infected pelvic hematoma.
†Popliteal thrombectomy and fasciotomies.
died intraoperatively or within the first 24 hours
after operation are the subject of an ongoing study.
Furthermore, the number of patients and adverse
clinical outcomes is small (Table III). However,
both of the patients with rupture who died had PF
1+2 levels 24 hours after operation that were con-
siderably higher than survivors, and one who died
10 days after surgery had very high t-PA activity and
very low PAI activity (indicating increased systemic
fibrinolysis) during and 24 hours after the operation.
A larger prospective study of the relationship
between hemostatic derangement and outcome in
patients undergoing repair of ruptured and nonrup-
tured AAAs is currently underway in our institution.
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Table IV. Hematocrit, platelet count, fibrinogen, PT, aPTT, and CRP in patients operated on for ruptured
and nonruptured AAAs
Ruptured AAA, Nonruptured AAA,
Assay (normal range) Sample point median (range) (n = 10) median (range) (n = 9) P value*
Hematocrit (0.37-0.54) A 0.31 (0.13-0.34) 0.42 (0.33-0.47) .0004
B 0.27 (0.18-0.44) 0.30 (0.25-0.37) NS
C 0.28 (0.22-0.42) 0.30 (0.23-0.35) NS
D 0.34 (0.26-0.42) 0.34 (0.25-0.39) NS
Platelet count (150-350 × 109/L) A 230 (119-303) 182 (75-744) NS
B 120 (81-189) 132 (103-541) NS
C 108 (59-146) 135 (91-577) NS
D 97 (50-133) 127 (85-604) NS
Fibrinogen (1.5-4.0 g/L) A 2.27 (0.86-3.75) 2.80 (1.59-6.02) NS
B 1.12 (0.88-2.51) 1.68 (0.72-5.39) NS
C 0.97 (0.46-1.82) 1.45 (0.36-5.44) NS
D 3.29 (1.76-4.63) 3.70 (2.50-8.98) NS
PT (10.5-14.5 s) A 14 (11-35) 12 (11-14) .009
B 20 (15-26) 17 (15-26) NS
C 20 (17-31) 20 (14-23) NS
D 16 (13-18) 14 (12-21) NS
aPTT (28-40 s) A 32 (28-126) 31 (25-49) NS
B 50 (34-210) 176 (56-240) .006
C 55 (42-210) 210 (79-240) .008
D 39 (32-76) 36 (29-39) .02
CRP (< 10 mg/L) A 6.7 (2.6-178.3) 4.3 (0.3-18.6) NS
B 3.0 (0.9-116) 5.0 (1.1-13.4) NS
C 3.8 (1.9-11.4) 2.0 (1.3-8.2) NS
D 105 (41.8-141.8) 92.4 (41.5-180.8) NS
Sample A, Immediately before induction of anesthesia; sample B, immediately before release of aortic clamp; sample C, 5 minutes after
aortic clamp release; sample D, 24 hours after aortic clamp release; NS, not significant.
*Mann-Whitney test.
Table V. PF 1+2, t-PA activity, and PAI activity in patients operated on for ruptured and nonruptured AAAs
Ruptured AAA, Nonruptured AAA,
Assay (normal range) Sample point median (range) (n = 10) median (range) (n = 9) P value*
PF 1+2 (0.4-1.1 nmol/L) A 9.0 (5.4-11.6) 2.2 (0.7-7.1) .0008
B 6.7 (3.3-8.9) 1.0 (0.9-4.0) .0003
C 6.5 (4.2-9.6) 2.0 (1.0-4.9) .0007
D 3.5 (1.9-11.4) 1.9 (1.3-5.6) NS
t-PA activity (0.2-2.0 IU/mL) A 0.12 (0.06-0.43) 0.49 (0.14-3.2) .009
B 0.27 (0.08-0.8) 0.91 (0.34-4.65) .0014
C 0.32 (0.09-4.53) 1.06 (0.19-5.62) .034
D 0.41 (0.15-2.1) 0.46 (0.21-1.45) NS
PAI activity (< 15 AU/mL) A 36.5 (20.6-38.8) 8.2 (3.2-21.7) .0003
B 38.6 (13.0-39.4) 10.8 (2.8-38.9) .0042
C 37.2 (10.6-39.4) 12.6 (2.2-28.7) .0055
D 18.1 (5.0-35.3) 14.7 (5.7-22.3) NS
Sample A, Immediately before induction of anesthesia; sample B, immediately before release of aortic clamp; sample C, 5 minutes after
aortic clamp release; sample D, 24 hours after aortic clamp release; NS, not significant.
*Mann-Whitney test.
The second question is whether therapeutic inter-
vention may ameliorate the adverse effects of this pro-
coagulant state and thus improve outcome. Apart
from the fact that patients in this study with ruptured
AAA sustained a period of preoperative hypovolemic
shock, the most obvious difference between the
groups relates to the use of systemic heparin during
aneurysm repair. The effects of heparin on the coagu-
lation parameters examined in the present study
include slight (5% to 10%) reduction in platelet count
in a small proportion of patients, prolongation of the
aPTT, marginal prolongation of the PT in a small
proportion of patients, elevation of the fibrinogen
level and a reduction in D-dimer levels due to a reduc-
tion in fibrin deposition, reduced PF 1+2 due to inhi-
bition of thrombin generation by antithrombin III,
and increased binding of thrombin to antithrombin
III but no increase in TAT levels. Other than t-PA, no
other fibrinolytic component appears to be affected
by heparin; whereas the majority of clinical and vol-
unteer studies have shown that repeated administra-
tion of unfractionated heparin over a number of days
increases t-PA antigen, short-term studies have shown
increases in t-PA activity similar in magnitude to what
might be expected due to diurnal variation and that
may be artifactual.23 Surgeons are naturally reluctant
to systemically heparinize a patient with a ruptured
aortic aneurysm, but these data suggest that after con-
trol of bleeding by aortic clamping, judicious use of
heparin may reverse the procoagulant state and may,
therefore, improve outcome from thrombotic com-
plications.24 It is important to note, however, that
patients with ruptured AAA exhibited very elevated
levels of TAT, which indicate that there is already a
considerable, albeit ineffective, attempt by nature to
inhibit thrombin activation. This may limit the effica-
cy of heparin in this situation. Other possible thera-
peutic interventions include angiotensin-converting
enzyme inhibitors (which may decrease PAI and
increase t-PA levels) and specific inhibitors of PAI
activity.25 There have been suggestions that patients
with ruptured AAA might benefit from antifibrinolyt-
ic therapy, specifically with aprotonin. However, this
has not been shown to be of therapeutic value in
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Table VI. Coagulation and fibrinolytic data for 2 patients who died after ruptured AAA repair compared
with 8 patients who survived
Nonsurvivor Nonsurvivor Survivors, median
Assay (normal range) Sample point (ARDS, ARF) (pneumonia, CLI) (range) (n = 8)
Platelet count (150-350 × 109/L) A 119 178 249 (156-303)
B 81 116 125 (96-189)
C 66 84 117 (59-146)
D 86 72 102 (50-133)
Fibrinogen (1.5-4.0 g/L) A 2.18 1.87 2.52 (0.86-3.75)
B 1.2 0.94 1.20 (0.88-2.51)
C 0.77 0.85 1.20 (0.46-1.82)
D 1.87 2.57 3.35 (1.76-4.63)
PT (10.5-14.5 s) A 16 14 14 (11-35)
B 23 18 20 (15-26)
C 27 24 20 (17-31)
D 18 15 16 (13-18)
aPTT (28-40 s) A 40 35 30 (28-126)
B 120 52 53 (34-210)
C 108 210 55 (42-123)
D 51 49 39 (32-76)
PF 1+2 (0.4-1.1 nmol/L) A 10.1 9.3 7.7 (5.4-11.6)
B 7.0 8.9 6.2 (3.3-8.4)
C 4.8 9.6 6.5 (4.2-8.0)
D 11.4 4.8 3.4 (1.9-4.4)
t-PA activity (0.2-2.0 IU/mL) A 0.13 0.11 0.17 (0.06-0.43)
B 0.8 0.12 0.27 (0.08-0.41)
C 4.53 0.43 0.28 (0.09-1.27)
D 2.1 0.25 0.41 (0.15-2.08)
PAI activity (< 15 AU/mL) A 31.0 36.4 36.7 (20.6-38.8)
B 13.0 38.9 38.6 (29.4-39.4)
C 10.6 38.2 37.2 (19.4-39.4)
D 5.9 22.2 18.1 (5.0-35.3)
Sample A, Immediately before induction of anesthesia; sample B, immediately before release of aortic clamp; sample C, 5 minutes after
aortic clamp release; sample D, 24 hours after aortic clamp release; ARDS, acute respiratory distress syndrome; ARF, acute renal failure;
CLI, critical lower limb ischemia.
reducing blood loss or blood transfusion requirement
in elective infrarenal aortic surgery,13 and the findings
of the present study strongly suggest that such thera-
py is contraindicated in patients undergoing operation
for ruptured aortic aneurysm.
At the present time, the triggering mechanisms
leading to this procoagulant state are unknown, but, as
it is present before operation in patients with rupture,
it is presumably related to whole body hypoperfusion
as a result of hemorrhagic shock. Although there was
no significant relationship between the degree of pre-
operative hypotension and any of the coagulation and
fibrinolytic parameters studied, there was a significant
negative correlation between operative blood loss and
fibrinogen level and platelet count during the opera-
tion, and a significant positive correlation between
operative blood loss and PT and aPTT during the
operation. The finding that certain patients undergo-
ing elective repair of nonruptured AAA also have ele-
vated levels of TAT and PF 1+2 (indicating patholog-
ic levels of thrombin generation) is difficult to explain
but may be related to the presence of thrombus with-
in the aneurysm sac.26 Indeed, both we and a number
of previous authors have suggested that patients with
AAA have a low-grade coagulopathy that may make
them particularly sensitive to the effects of hypoten-
sion and ischemia.5,27,28 Previous work from this
group has demonstrated morphologic evidence of
endothelial cell activation before operation in patients
with ruptured AAA, suggesting that this may be an
early event in this group of patients.29 Tissue factor
expression is associated with thrombin generation and
reduced fibrinolysis,30,31 and its role in the pathophys-
iology of the hemostatic derangement in patients with
ruptured AAA is currently being investigated.
In conclusion, these novel data demonstrate that
ruptured AAA repair is associated with inhibition of
systemic fibrinolysis and intense thrombin genera-
tion. This procoagulant state may contribute to
microvascular and macrovascular thrombosis that, in
turn, lead to the common causes of perioperative
morbidity and mortality, namely myocardial infarc-
tion, multiple organ failure, and thromboembolism.
We thank Pamela Dawson, Department of Haema-
tology, Royal Infirmary of Edinburgh, and Wesley Stuart,
Vascular Surgery Unit, Royal Infirmary of Edinburgh, for
technical assistance. 
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